Funding Opportunity RFA-MH-21-112 from the NIH Guide for Grants and Contracts. This SBIR Funding Opportunity Announcement (FOA) is intended to support small businesses to develop and test service-ready, commercially viable tools and technologies for suicide prevention, including technologies that can be used to advance training, quality monitoring, a?nd quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Given the focus on practice-ready accessible resources and products that could be readily integrated into practice, NIMH encourages the use of technology and other design features that make the tools scalable and robust against implementation drift, and a deployment-focused approach that takes into account the perspectives of key stakeholders (e.g., service users, providers, administrators) and system-level factors, such as workforce capacity that influence potential integration of tools into clinical workflows.

Funding Opportunity RFA-MH-21-111 from the NIH Guide for Grants and Contracts. NIMH seeks applications for pilot effectiveness projects to evaluate the preliminary effectiveness of service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Given the focus on practice-ready accessible resources and products that could be readily integrated into practice, NIMH encourages the use of technology and other design features that make the tools scalable and robust against implementation drift, and a deployment-focused? approach that takes into account the perspectives of key stakeholders (e.g., service users, providers, administrators) and system-level factors, such as workforce capacitythat influence potential integration of tools into clinical workflows. This FOA supports pilot effectiveness research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of service-ready tools and technologies for suicide prevention and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on service-ready tools and technologies or suicide prevention is provided via the R01 in RFA-MH-21-110. Support for SBIR studies focused on service-ready tools and technologies or suicide prevention is provided via the R4?3?/?R?4?4 in RFA-MH-21-112.

Funding Opportunity RFA-MH-21-110 from the NIH Guide for Grants and Contracts. NIMH seeks applications for research projects to evaluate the effectiveness of service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Given the focus on practice-ready accessible resources and products that could be readily integrated into practice, NIMH encourages the use of technology and other design features that make the tools scalable and robust against implementation drift, and a deployment-focused approach that takes into account the perspectives of key stakeholders (e.g., service users, providers, administrators) and system-level factors, such as workforce capacity that influence potential integration of tools into clinical workflows. This FOA is intended to support effectiveness research of service-ready tools and technologies for suicide prevention that are statistically powered to provide a definitive answer regarding the study tool's effectiveness. Support for pilot effectiveness research to evaluate the initial feasibility, tolerability, acceptability, safety, and preliminary indications of effectiveness of service-ready tools and technologies for suicide prevention is provided via the R34 in RFA-21-111.Support for SBIR studies focused on service-ready tools and technologies or suicide prevention is provided via the R43/R44 in RFA-21-112.

Notice NOT-DA-21-009 from the NIH Guide for Grants and Contracts

Notice NOT-AI-21-003 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-025 from the NIH Guide for Grants and Contracts

Notice NOT-DA-20-096 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-020 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-036 from the NIH Guide for Grants and Contracts. NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)

Notice NOT-NR-20-007 from the NIH Guide for Grants and Contracts

Notice NOT-DA-21-010 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-033 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD). Applicants are strongly encouraged to consult the NCI DCTD website at https://dctd.cancer.gov/ to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA.

Notice NOT-RM-21-008 from the NIH Guide for Grants and Contracts

Notice NOT-RM-21-007 from the NIH Guide for Grants and Contracts

Notice NOT-RM-21-006 from the NIH Guide for Grants and Contracts

Notice NOT-RM-21-002 from the NIH Guide for Grants and Contracts

Notice NOT-RM-21-003 from the NIH Guide for Grants and Contracts

Notice NOT-RM-21-001 from the NIH Guide for Grants and Contracts

Notice NOT-EB-20-022 from the NIH Guide for Grants and Contracts

Notice NOT-AI-21-002 from the NIH Guide for Grants and Contracts